NEW YORK – South San Francisco-based Veracyte and MaviDx said on Wednesday they have signed an agreement for MaviDx to develop ultra-high throughput genomic testing for SARS-CoV-2 on Veracyte's nCounter diagnostic platform.
As part of the collaboration, Miami-based MaviDx will develop, validate, secure regulatory approvals for, and commercialize SARS-CoV-2 and other infectious disease tests, including for influenza, on the nCounter system.